These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31418585)

  • 1. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.
    Bilezikian JP; Hattersley G; Mitlak BH; Hu MY; Fitzpatrick LA; Dabrowski C; Miller PD; Papapoulos SE
    Curr Med Res Opin; 2019 Dec; 35(12):2097-2102. PubMed ID: 31418585
    [No Abstract]   [Full Text] [Related]  

  • 2. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
    Miller PD; Schwartz EN; Chen P; Misurski DA; Krege JH
    Osteoporos Int; 2007 Jan; 18(1):59-68. PubMed ID: 17013567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.
    Cosman F; Peterson LR; Towler DA; Mitlak B; Wang Y; Cummings SR
    J Clin Endocrinol Metab; 2020 Nov; 105(11):3384-95. PubMed ID: 32658264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
    Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D
    Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture.
    Saag KG; Williams SA; Wang Y; Weiss RJ; Cauley JA
    Clin Ther; 2020 Jun; 42(6):1099-1107.e1. PubMed ID: 32513495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
    Watts NB; Hattersley G; Fitzpatrick LA; Wang Y; Williams GC; Miller PD; Cosman F
    Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.
    McClung MR; Harvey NC; Fitzpatrick LA; Miller PD; Hattersley G; Wang Y; Cosman F
    Menopause; 2018 Jul; 25(7):767-771. PubMed ID: 29462094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
    Leder BZ; Mitlak B; Hu MY; Hattersley G; Bockman RS
    J Clin Endocrinol Metab; 2020 Mar; 105(3):938-43. PubMed ID: 31674644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abaloparatide: A new pharmacological option for osteoporosis.
    Sleeman A; Clements JN
    Am J Health Syst Pharm; 2019 Jan; 76(3):130-135. PubMed ID: 30689744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.
    Miller PD; Troy S; Weiss RJ; Annett M; Schense J; Williams SA; Mitlak B
    Clin Drug Investig; 2021 Mar; 41(3):277-285. PubMed ID: 33638863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
    Le QA; Hay JW; Becker R; Wang Y
    Ann Pharmacother; 2019 Feb; 53(2):134-143. PubMed ID: 30160186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.
    Merlotti D; Falchetti A; Chiodini I; Gennari L
    Expert Opin Pharmacother; 2019 May; 20(7):805-811. PubMed ID: 30856013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.
    Reginster JY; Al Daghri NM; Bruyere O
    Expert Opin Pharmacother; 2017 Dec; 18(17):1811-1813. PubMed ID: 29048260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study.
    Cosman F; Cooper C; Wang Y; Mitlak B; Varughese S; Williams SA
    Osteoporos Int; 2022 Aug; 33(8):1703-1714. PubMed ID: 35524068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.
    Boyce EG; Mai Y; Pham C
    Ann Pharmacother; 2018 May; 52(5):462-472. PubMed ID: 29241341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.
    Jamal SA; Bauer DC; Ensrud KE; Cauley JA; Hochberg M; Ishani A; Cummings SR
    J Bone Miner Res; 2007 Apr; 22(4):503-8. PubMed ID: 17243862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide.
    Reginster JY; Hattersley G; Williams GC; Hu MY; Fitzpatrick LA; Lewiecki EM
    Calcif Tissue Int; 2018 Nov; 103(5):540-545. PubMed ID: 29951742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.